Blaise Pasquiers
Overview
Explore the profile of Blaise Pasquiers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
13
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alexandre J, Oudard S, Golmard L, Campedel L, Mseddi M, Ladoire S, et al.
Clin Pharmacokinet
. 2024 Jul;
63(7):1025-1036.
PMID: 38963459
Background And Objective: Trough abiraterone concentration (ABI C) of 8.4 ng/mL has been identified as an appropriate efficacy threshold in patients treated for metastatic castration-resistant prostate cancer (mCRPC). The aim...
2.
Puszkiel A, Bianconi G, Pasquiers B, Balakirouchenane D, Arrondeau J, Boudou-Rouquette P, et al.
Br J Cancer
. 2024 Mar;
130(11):1866-1874.
PMID: 38532102
Background: Reducing nivolumab dose intensity could increase patients' life quality and decrease the financial burden while maintaining efficacy. The aims of this study were to develop a population PK model...
3.
Pasquiers B, Benamara S, Felices M, Ternant D, Decleves X, Puszkiel A
Pharmaceutics
. 2023 Aug;
15(8).
PMID: 37631343
Interspecies translation of monoclonal antibodies (mAbs) pharmacokinetics (PK) in presence of target-mediated drug disposition (TMDD) is particularly challenging. Incorporation of TMDD in physiologically based PK (PBPK) modeling is recent and...
4.
Pasquiers B, Benamara S, Felices M, Nguyen L, Decleves X
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36361546
The interest in therapeutic monoclonal antibodies (mAbs) has continuously growing in several diseases. However, their pharmacokinetics (PK) is complex due to their target-mediated drug disposition (TMDD) profiles which can induce...
5.
Jurkiewicz E, Tsvetkova S, Grinberg A, Pasquiers B
Invest Radiol
. 2022 Mar;
57(8):510-516.
PMID: 35318970
Objectives: The aim of this study was to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of gadopiclenol, a new high-relaxivity gadolinium-based contrast agent, in children aged 2 to 17...